EP1322182A2 - Mittel mit verlängerter magenverweilzeit zur erzeugung eines langanhaltenden sättigungseffektes sowie dessen verwendung - Google Patents
Mittel mit verlängerter magenverweilzeit zur erzeugung eines langanhaltenden sättigungseffektes sowie dessen verwendungInfo
- Publication number
- EP1322182A2 EP1322182A2 EP01978347A EP01978347A EP1322182A2 EP 1322182 A2 EP1322182 A2 EP 1322182A2 EP 01978347 A EP01978347 A EP 01978347A EP 01978347 A EP01978347 A EP 01978347A EP 1322182 A2 EP1322182 A2 EP 1322182A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- agent according
- fatty acids
- viscosity
- agent
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000694 effects Effects 0.000 title claims abstract description 14
- 230000005923 long-lasting effect Effects 0.000 title claims abstract description 12
- 210000002784 stomach Anatomy 0.000 title claims description 11
- 230000014759 maintenance of location Effects 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 33
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000002830 appetite depressant Substances 0.000 claims abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 24
- 239000000194 fatty acid Substances 0.000 claims description 24
- 229930195729 fatty acid Natural products 0.000 claims description 24
- 150000004665 fatty acids Chemical group 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 12
- 230000036186 satiety Effects 0.000 claims description 11
- 235000019627 satiety Nutrition 0.000 claims description 11
- -1 compressed Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 235000021395 porridge Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000008119 colloidal silica Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 244000303965 Cyamopsis psoralioides Species 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- 235000015099 wheat brans Nutrition 0.000 description 4
- 229920002907 Guar gum Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000130592 Hibiscus syriacus Species 0.000 description 1
- 235000018081 Hibiscus syriacus Nutrition 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000012820 baking ingredients and mixes Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/29—Mineral substances, e.g. mineral oils or clays
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention relates to an agent for oral administration to produce a long-lasting satiety effect, comprising at least one substance which increases the viscosity of a liquid and at least one further compound which increases the residence time of the viscosity-increasing substance in the stomach.
- Preparations with gel-forming substances that develop their long-lasting, satiating effect via the gastrointestinal tract in the form of tablets, granules, suspensions or solutions are used for treatment, e.g. B. from overweight and diseases caused by obesity.
- Appropriate preparations contain herbal mucilage and swelling agents, such as. B. alginates, pectin, wheat bran, starch gels or guar flour. With an ingestion fluid together or in the presence of gastric fluid, these substances form a gel-like structure, so-called hydrode or hydrocolloids, which among other things. can serve the saturation.
- the present invention relates to an agent for oral administration to produce a long-lasting satiety effect, comprising at least one substance which increases the viscosity of a liquid and at least one further compound which increases the residence time of the viscosity-increasing substance to prolong a satiety effect in the stomach.
- fatty acids and / or fatty acid derivatives are added as a further compound to the substances used to form gel or pulp or to increase the viscosity of liquids.
- Fatty acids and / or fatty acid derivatives lead to a slowdown in gastric emptying and thus to the desired increased gastric dwell time.
- the agents according to the invention do not contain any drugs that have a systemic, pharmacological effect. Drugs which have a systemic, pharmacological effect are understood to mean those drugs which, after absorption, are distributed in the blood stream and thus reach the site of action.
- the agents according to the invention are further characterized in that they contain fatty acids with at least 6 carbon atoms in the molecule, their salts and / or derivatives thereof. According to the invention, these can be saturated and / or unsaturated fatty acids.
- the agent according to the invention can contain fatty acids with a carbon chain of length in the range from do to C 2 o, preferably C-12 to Cis, particularly preferably C 13 to C 16 .
- fatty acids is mentioned here as an example, but these are not limiting for the present invention.
- Salts and / or derivatives of the fatty acids are also included according to the invention. These can be, for example, alkali and / or ammonium salts and / or various fatty acid esters. Examples include glycerol esters such as. B. fats in which the fatty acids can be bound. Furthermore, the fatty acids can be chemically bound in lecithin and released by enzymatic processes during digestion in the gastrointestinal tract, in order subsequently to bring about the desired function of extending the residence time of the agent according to the invention.
- the fatty acids can be incorporated into the agent according to the invention in finely dispersed form by trituration with colloidal silica.
- the solubility of the fatty acids in the agent according to the invention is improved.
- the agent according to the invention can contain fatty acids in a proportion of 0.7 to 70 mg / g, preferably 2.5 to 50 mg / g and particularly preferably 10 to 20 mg / g of viscosity-increasing substance.
- a viscosity-increasing substance is to be understood as a mostly organic and high-molecular substance
- gels are to be understood as meaning dimensionally stable, easily deformable systems which result from the interaction of high-molecular substances with liquids.
- the substances referred to as gel formers form three-dimensional networks in which liquid molecules (dispersants) are incorporated. If the dispersant is a liquid, one speaks of lyogels; if it is water, the gels are called hydrogels.
- the gels have no firm connections between the cavities filled with liquid or gas, as is the case with sponges or sponge-like structures.
- the agent for achieving a long-lasting saturation effect contains, in addition to the aforementioned fatty acids, their salts and / or derivatives as a viscosity-increasing substance, natural, synthetic and / or semi-synthetic polysaccharides and / or polyacids and / or mixtures thereof.
- Examples of this are well known, e.g. B. agar-agar, alginic acid, alginates, laminarin, fucoidin, lentinan, schitophyllan, acacia gum, carrageenan, guar gum, St. John's wort, galactomannans, tragacanth, hyaluronic acid, althea mucus, quince mucus, psyllium mucus, xanthanymethyl cellulose , Pectins, dextrans, dextrin, cellulose, acacia, gelatin, soy, starch and / or their derivatives and / or mixtures thereof.
- Preferred embodiments of the agent according to the invention contain guar gum and / or methyl cellulose and / or starch derivatives.
- guar gallactomannan is particularly preferred and / or guar gum and / or hydroxymethyl cellulose
- Carboxymethyl cellulose and / or hydroxyethyl starch and / or mixtures of the aforementioned substances are particularly useful as carboxymethyl cellulose and / or hydroxyethyl starch and / or mixtures of the aforementioned substances.
- the agent is in the form of a powder, granules, compressed, pellet, tablet, capsule, solution, dispersion, slurry and / or any other suitable formulation.
- the agent can be dissolved and / or dispersed in a hydrophilic or lipophilic medium.
- Media which are particularly suitable according to the invention are water, milk drinks, fruit juices and / or oil.
- the preparation can be carried out by stirring the agent according to the invention into these liquids and / or can be processed into a slurry by heating.
- the agent according to the invention can contain gas-forming substances.
- these gas-generating substances can support the formation of a gel.
- the agent according to the invention can contain shower mixtures.
- the shower mix can preferably be flavored.
- the present invention also relates to the use of a previously mentioned agent as an additive to foods, for the production of nutritional supplements, appetite suppressants and / or
- Food are used, but also before, during and / or after eating food and so one longer residence time of the food combined with a long-lasting satiety effect in the stomach.
- the C- ⁇ 4 fatty acid is finely rubbed with the colloidal silica and then sieved (mesh size 0.3 mm).
- the trituration of the fatty acid with the colloidal silica is mixed with the guar flour. This is then followed by granulation with purified water. The granules are dried at 45 ° C.
- the fatty acids are triturated homogeneously with the table salt and colloidal silica.
- 3 to 6 g of the granules described in Preparation 1 are distributed in 150 ml of multivitamin juice with stirring.
- the suspension of the granules is drunk in the multivitamin juice within the first minute after being added.
- the feeling of satiety lasts for about 2 to 3 hours.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10044846 | 2000-09-11 | ||
| DE10044846A DE10044846A1 (de) | 2000-09-11 | 2000-09-11 | Mittel mit verlängerter Magenverweilzeit zur Erzeugung eines langanhaltenden Sättigungseffektes sowie dessen Verwendung |
| PCT/EP2001/010309 WO2002019842A2 (de) | 2000-09-11 | 2001-09-07 | Mittel mit verlängerter magenverweilzeit zur erzeugung eines langanhaltenden sättigungseffektes sowie dessen verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1322182A2 true EP1322182A2 (de) | 2003-07-02 |
Family
ID=7655784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01978347A Withdrawn EP1322182A2 (de) | 2000-09-11 | 2001-09-07 | Mittel mit verlängerter magenverweilzeit zur erzeugung eines langanhaltenden sättigungseffektes sowie dessen verwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20030161885A1 (enExample) |
| EP (1) | EP1322182A2 (enExample) |
| JP (1) | JP2004508310A (enExample) |
| AU (1) | AU2002210491A1 (enExample) |
| CA (1) | CA2419389A1 (enExample) |
| DE (1) | DE10044846A1 (enExample) |
| WO (1) | WO2002019842A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10247910A1 (de) * | 2002-10-14 | 2004-04-22 | Beisel, Günther | Mittel zur Erzeugung eines langanhaltenden Sättigungseffektes |
| EP1572238A1 (de) * | 2002-12-19 | 2005-09-14 | Günther Beisel | Mittel mit retardierter stofffreisetzung |
| WO2004056199A1 (de) * | 2002-12-19 | 2004-07-08 | Beisel Guenther | Zubereitung zur appetitminderung, sättigung und/oder gewichtsreduktion für kinder |
| EP3188713B2 (en) * | 2014-08-11 | 2024-04-10 | perora GmbH | Method of inducing satiety |
| LT3188717T (lt) * | 2014-08-11 | 2020-03-25 | Perora Gmbh | Vaisto forma, apimanti daleles |
| CA2989510A1 (en) | 2015-07-07 | 2017-01-12 | Perora Gmbh | Method of inducing satiety |
| AU2017220691A1 (en) | 2016-02-18 | 2018-08-09 | Perora Gmbh | Kits comprising satiety-inducing formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756450A (en) * | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
| US5855917A (en) * | 1996-12-04 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein comprising 20-carbon conjugated unsaturated fatty acids |
| US6054480A (en) * | 1997-09-18 | 2000-04-25 | Nectra, Inc. | Fatty acids as a diet supplement |
-
2000
- 2000-09-11 DE DE10044846A patent/DE10044846A1/de not_active Ceased
-
2001
- 2001-09-07 JP JP2002524334A patent/JP2004508310A/ja active Pending
- 2001-09-07 AU AU2002210491A patent/AU2002210491A1/en not_active Abandoned
- 2001-09-07 CA CA002419389A patent/CA2419389A1/en not_active Abandoned
- 2001-09-07 EP EP01978347A patent/EP1322182A2/de not_active Withdrawn
- 2001-09-07 US US10/363,090 patent/US20030161885A1/en not_active Abandoned
- 2001-09-07 WO PCT/EP2001/010309 patent/WO2002019842A2/de not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0219842A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002019842A3 (de) | 2007-11-15 |
| JP2004508310A (ja) | 2004-03-18 |
| CA2419389A1 (en) | 2003-02-20 |
| US20030161885A1 (en) | 2003-08-28 |
| AU2002210491A1 (en) | 2002-03-22 |
| WO2002019842A2 (de) | 2002-03-14 |
| DE10044846A1 (de) | 2002-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5118510A (en) | Niacin drink mix formulation | |
| DE69916288T2 (de) | Lipasehemmer und chitosan enthaltende arzneimittel | |
| DE69107046T2 (de) | Algin enthaltende Nahrungsmittel und Getränke. | |
| DE68907835T3 (de) | Direkt verpressbare Füllstoffe zur verzögerten Freisetzung. | |
| DE60118893T2 (de) | Insulinprodukte mit verbesserten nahrungseigenschaften | |
| DE3779933T2 (de) | Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung. | |
| DE69531900T2 (de) | Cerealien enthaltendes lebensmittel mit einem hohen gehalt an löslichen ballaststoffen | |
| JPH0745521B2 (ja) | 高血圧降下作用を有する高血圧降下剤 | |
| US5932561A (en) | Dietary composition with lipid binding properties for weight management and serum lipid reduction | |
| JP2010517542A (ja) | アルギン酸塩を含むダイエット食品 | |
| DE69624364T2 (de) | Abführmittel enthaltend lactitol und psyllium | |
| DE60307249T2 (de) | Eisen-dextrin verbindung zur behandlung von anämien durch eisenmangel | |
| WO2003053451A1 (de) | Verwendung von ionischen und nichtionischen celluloseethern zur herstellung eines gelartigen mittels zur verhinderung der resorption von fetten aus dem magen-darm-trakt | |
| EP0471967A1 (de) | Sucralfat-Kautablette | |
| EP1322182A2 (de) | Mittel mit verlängerter magenverweilzeit zur erzeugung eines langanhaltenden sättigungseffektes sowie dessen verwendung | |
| DE3613219C2 (enExample) | ||
| JP2983716B2 (ja) | 水溶性食物繊維コンプレックスを含む食品組成物 | |
| DE20016260U1 (de) | Mittel mit verlängerter Magenverweilzeit zur Erzeugung eines langanhaltenden Sättigungseffektes | |
| DE69201077T2 (de) | Alginsäure enthaltende Arzneisuspension. | |
| CA2030448A1 (en) | Niacin drink mix formulation | |
| DE102006044448B4 (de) | Gelartiges Basenpräparat zur Supplementierung von Spurenelementen und Verfahren zu dessen Herstellung | |
| DE69208842T2 (de) | Tabletten mit verzögerter Freisetzung | |
| WO1998008877A1 (en) | Chitosan derivatives, process for producing the same and uses of the same | |
| DE102006001035A1 (de) | Mittel für die perorale Applikation zur Verzögerung der Resorption von Stoffen | |
| RU2251934C2 (ru) | Биологически активная пищевая добавка |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20030205 |
|
| AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| 17Q | First examination report despatched |
Effective date: 20050107 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20061128 |
|
| R17D | Deferred search report published (corrected) |
Effective date: 20071115 |